Anti-PVRIG antibody COM701 shows antitumor activity in early studies
-
Last Update: 2020-06-23
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Compugen Pharmaceuticals today announced that data to be presented at the 2020 annual meeting of the American Association for Cancer Research (AACR) show that experimental anti-PVRIG antibody COM701 showed high disease control rates in the Phase I studyongoing trials aimed at assessing the safety and tolerance of comatose single therapy in an increasing dose and opdivo (nivolumab) in combination with PersimmonThe study included preliminary anti-tumor activity, pharmacokinetics, and pharmacodynamics of selected tumor types, including non-small cell lung cancer, ovarian cancer, breast cancer, endometrial cancer, and colorectal cancerCom701 is well tolerated and no dose-restrictive toxicity has been observed in a single drug or in combination with OpdivoAt the same time, the disease control rate was 69% among the 16 patients given COM701, and among the 12 subjects who were used with Opdivo (nivolumab), the disease control rate rose to 75%
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
